3,840 Shares in Edwards Lifesciences Corporation $EW Purchased by Arkadios Wealth Advisors

Arkadios Wealth Advisors purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 3,840 shares of the medical research company’s stock, valued at approximately $300,000.

A number of other hedge funds also recently bought and sold shares of the stock. Jennison Associates LLC raised its position in Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after purchasing an additional 1,584,958 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Edwards Lifesciences by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after purchasing an additional 264,311 shares in the last quarter. Nuveen LLC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $330,881,000. Invesco Ltd. raised its position in Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after purchasing an additional 107,241 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Edwards Lifesciences by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after purchasing an additional 198,882 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 1.5%

NYSE:EW opened at $82.86 on Thursday. The stock’s 50 day moving average price is $77.72 and its 200 day moving average price is $77.18. The company has a market capitalization of $48.65 billion, a PE ratio of 11.92, a P/E/G ratio of 3.97 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $87.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of analyst reports. Barclays reaffirmed an “overweight” rating and issued a $99.00 price target (up previously from $95.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Stifel Nicolaus increased their price objective on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a report on Friday, October 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Morgan Stanley increased their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Finally, UBS Group reiterated a “neutral” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.